Streasure4Health is developing the first objective test for chronic fatigue and post-exertional malaise (PEM)—a core exhausting and disabling symptom in disorders such as Long COVID, burnout, and PTSD, affecting over 250 million people worldwide.

SupraVision is developing an innovative cell therapy for age-related macular degeneration (AMD) to restore lost vision by replacing damaged retinal tissue.

SynTEG therapeutics is developing synTEG-01, an autologous engineered T-cell therapy that targets a metabolic dysregulation induced antigen complex on cancer cells across multiple tumor types.

A CT-guided robotic solution that improves the accuracy and safety of lung biopsies by compensating for patient breathing.

T Cell Factory (TCF) will identify and develop therapeutic T cell receptor (TCR) genes for the growing market of cancer therapies.

We at TargED have developed MICROLYSE, an innovative fusion-protein that has an antibody domain that recognizes microthrombi and an enzymatic domain that breaks them down.

thromboDx BV is a molecular diagnostics company that develops and commercialises blood-based diagnostics through its proprietary platelet-powered technology platform

THRONCAT Analytics offers a service in optimizing mRNA sequences for safety by detecting, identifying, and quantifying protein by-products of mRNA therapeutics.

At Toxys we strongly believe in bringing high quality information to our partners and clients. I strongly believe that the future for human safety assessment is not with simple tests that only provide a yes or no answers, but advanced in vitro models that provide reliable and relevant insight into the mechanism of action of novel chemicals and materials. We are committed to support our partners in understanding their latest compounds and in making the right decisions during R&D of novel products

At TrianecT, we develop StrokePointer: a fast pre-hospital solution for early stroke diagnosis.